Tag: GlobeNewswire

– Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors –

– Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients –

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) — Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a poster will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 4-8, 2026, in Phoenix, AZ, demonstrating that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumor models. These findings support Immuneering’s plans to conduct a Phase 2 study of atebimetinib in combination with PD-1 blockade in patients with lung cancer.

Poster Presentation Details:
Title: Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the pulsatile MEK inhibitor, Atebimetinib, enhances PD-1 checkpoint blockade in RAS mutant tumors.
Lead author: Amy E. Axel, Immuneering
Abstract Number: 377
Date and Time: Friday, November 6, 2026, 10:00 a.m. MT

Following presentation, the poster will be available on the publications section of Immuneering’s website at https://immuneering.com/publications.

About Immuneering Corporation
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.

Forward-Looking Statements

This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer including modified Gemcitabine/nab-paclitaxel (mGnP) and checkpoint inhibitors; and that preclinical data demonstrating enhancement of PD-1 checkpoint blockade in RAS mutant tumors may translate into human clinical trials.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we are a late-stage clinical oncology company with a limited operating history and have not completed any registrational clinical trials; we have incurred significant losses, are not currently profitable and may never become profitable; limitations on our cash runway and potential increases in expenditures; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and changing regulatory standards, and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including the uncertainty of whether positive preclinical or early clinical efficacy and safety results are confirmed in later-stage trials, potential delays in activation of trial sites or enrollment of trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.

These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Contact:
Laurence Watts
New Street Investor Relations
laurence@newstreetir.com

Media Contact:
David Caouette
dcaouette@immuneering.com

AB “Ignitis grupė” (hereinafter – the Group) announces that Kepler Cheuvreux, a leading independent European financial services company, with a strong presence in equity research and brokerage, has initiated sponsored research of the Group’s stock and published the initiation report.

Its research includes insights on the Group’s performance, potential, estimates and valuation. The initiation report and subsequent updates will be publicly available on Kepler Cheuvreux Research Hub here.

“We welcome Kepler Cheuvreux’s initiation of equity research coverage of Ignitis Group. As Europe’s leading independent equity broker, Kepler Cheuvreux brings an additional independent perspective on our performance, strategy and long-term value creation. Its analysis will further strengthen our visibility and engagement across the capital markets,” says Jonas Rimavičius, CFO and member of the Management Board of Ignitis Group.

The recommendations and consensus of equity research analysts covering the Group’s stock is available here.

Legal notice:
The research is prepared by Kepler Cheuvreux under a sponsored research arrangement and reflects the independent views of its authors. The reports are prepared based on publicly available information, provided for information purposes only and does not constitute investment advice or a recommendation to buy, sell or hold securities. The Group assumes no responsibility for the analyses, opinions or conclusions contained in the report. Any investment decision remains solely the responsibility of the investor.

For additional information, please contact:

Communications
Valdas Lopeta
+370 621 77993
valdas.lopeta@ignitis.lt 

Investor Relations
Ainė Riffel-Grinkevičienė
+370 643 14925
aine.riffel-grinkeviciene@ignitis.lt

• agenT-797 enables tumor-cell killing in a human relevant model of checkpoint inhibitor–resistant colorectal cancer liver metastases
• Native and engineered iNKT cells eliminate senescent tumor cells and fibroblasts in preclinical models, supporting complementary approaches to cancer treatment

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced two poster presentations at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The presentations address two distinct areas of cancer research: tumor-cell killing in checkpoint inhibitor–resistant colorectal cancer liver metastases and elimination of senescent tumor cells and fibroblasts.

The first presentation examines agenT-797 alone and in combination with botensilimab and balstilimab (BOT+BAL) in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases. This preclinical research supports the rationale for the ongoing Phase 2 trial at Scripps, led by Darren Sigal, M.D., evaluating the combination in patients with previously treated microsatellite-stable (MSS) metastatic colorectal cancer with liver metastases (NCT07550088).

The second examines native agenT-797 and engineered MiNK-215, a FAP-targeting CAR-iNKT cell therapy incorporating IL-15, in oncogenic in vitro models of senescent tumor cells and fibroblasts.

Together, the presentations highlight complementary opportunities for MiNK’s platform; addressing treatment-resistant cancer and targeting senescent cancer and stromal cells.

Poster Presentation Details

Title: Native and engineered allogenic invariant natural killer T (iNKT) cells eliminate senescent tumor cells and fibroblasts in oncogenic in vitro models
Presenter: Jing Fang, Ph.D., Postdoctoral Fellow in the laboratory of Jesús Gil, MRC London Institute of Medical Sciences, Imperial College London, London, United Kingdom.
Date: Friday, November 6, 2026
Times: 12:15–1:45 p.m.; 6:40–8:10 p.m. MST
Location: Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4–6
Poster No.: 177

Title: agenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
Presenter: Shanmugarajan Krishnan, Ph.D., M.S., B.S.; Agenus Inc., Lexington, MA
Date: Saturday, November 7, 2026
Times: 12:15–1:45 p.m.; 6:40–8:10 p.m. MST
Location: Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4–6
Poster No.: 270

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK’s proprietary platform is designed to restore immune balance and drive cytotoxic responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK’s lead candidate, agenT-797, is an off-the-shelf iNKT cell therapy currently in clinical development for GVHD, solid tumors, and severe pulmonary inflammation. With a scalable cryopreserved manufacturing process and differentiated biology bridging innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies. For more information, visit www.minktherapeutics.com or follow us on X @MiNK_iNKT.

About agenT-797

AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as “master regulators,” combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors. Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al. AACR IO 2024, Oncogene. 2024) and combat inflammation in critically ill patients with severe respiratory pathology (Nature Communications. 2024).

About MiNK-215

MiNK-215 is an investigational, allogeneic, off-the-shelf CAR-iNKT cell therapy engineered to target fibroblast activation protein (FAP) expressed on stromal cells within the tumor microenvironment. MiNK-215 also incorporates soluble IL-15, designed to enhance cell persistence and immune activation. (Cancer Immunology Research)

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, safety, and anticipated benefits of agenT-797; clinical trial design, timing, and enrollment; and MiNK’s broader development plans. These statements are subject to risks and uncertainties detailed in MiNK’s most recent filings with the Securities and Exchange Commission. MiNK cautions investors not to place undue reliance on these statements, which speak only as of the date of this release.

Contacts:

Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com

BEIJING, China, Oct. 02, 2026 (GLOBE NEWSWIRE) — iTonic Holdings Ltd (Nasdaq: ITOC) (the “Company”), a healthcare company developing digital medical technologies, today announced that at the extraordinary general meeting (the “EGM”) held on September 9, 2026, shareholders approved, among other matters, a 16-for-1 consolidation of the Company’s class A ordinary shares (the “Class A Ordinary Shares”) and class B ordinary shares (the “Class B Ordinary Shares”) (the “Share Consolidation”) and a related increase in authorized share capital. The Share Consolidation will combine every sixteen (16) issued and unissued Class A Ordinary Shares, par value US$0.0001 each, into one (1) Class A Ordinary Share, par value US$0.0016, and every sixteen (16) issued and unissued Class B Ordinary Shares, par value US$0.0001 each, into one (1) Class B Ordinary Share, par value US$0.0016.

The Share Consolidation will take effect at 12:01 a.m. Eastern Time on October 6, 2026 (the “Effective Date”), subject to completion of applicable corporate requirements and The Nasdaq Stock Market LLC (“Nasdaq”) not objecting. Upon the opening of the market on October 6, 2026, the Company’s Class A Ordinary Shares are expected to begin trading on The Nasdaq Capital Market on a post-Share Consolidation basis under the current symbol “ITOC”. The new CUSIP number for the Class A Ordinary Shares following the Share Consolidation will be G71399110, replacing the current CUSIP number G71399102.

The Share Consolidation will reduce the issued and outstanding Class A Ordinary Shares from 109,382,000 to approximately 6,836,375 and the issued and outstanding Class B Ordinary Shares from 7,668,000 to approximately 479,250. No fractional shares will be issued in connection with the Share Consolidation. Any fractional entitlement resulting from the Share Consolidation will be rounded up to the next whole Class A Ordinary Share or Class B Ordinary Share, as applicable.

Immediately following the Share Consolidation, the Company’s authorized share capital will remain US$50,000, divided into 25,000,000 Class A Ordinary Shares and 6,250,000 Class B Ordinary Shares, each of par value US$0.0016. The related share capital increase approved at the EGM will then increase the authorized share capital to US$800,000, divided into 400,000,000 Class A Ordinary Shares and 100,000,000 Class B Ordinary Shares, each of par value US$0.0016 (the “Share Capital Increase”). The Share Capital Increase creates additional authorized but unissued shares and does not itself increase the number of shares outstanding. The fourth amended and restated memorandum and articles of association approved at the EGM will take effect upon the Share Consolidation and the Share Capital Increase becoming effective.

Proportionate adjustments will be made, as applicable, to the number of shares issuable and the exercise or conversion prices under any outstanding options, warrants and convertible or exchangeable securities, and to share reserves under the Company’s equity incentive plans, in accordance with their respective terms.

The Share Consolidation is intended to increase the trading price per Class A Ordinary Share to support the Company’s efforts to regain compliance with the US$1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As previously disclosed, Nasdaq granted the Company until October 19, 2026 to regain compliance. There can be no assurance that the Share Consolidation will enable the Company to regain or maintain compliance with Nasdaq’s listing requirements.

About iTonic Holdings Ltd

iTonic Holdings Ltd (Nasdaq: ITOC) is a technology-driven healthcare company focused on developing innovative digital medical solutions. Through strategic investments and technology partnerships, the Company seeks to advance healthcare transformation through artificial intelligence, automation and intelligent data platforms. For more information, please visit: http://www.ftzy.com.cn/ir/overview.php

Forward-Looking Statements

This press release contains forward-looking statements under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These include statements about the anticipated timing and implementation of the Share Consolidation, the Share Capital Increase and the amended and restated memorandum and articles of association; the number of shares outstanding after the Share Consolidation; post-consolidation trading and share prices; and the Company’s ability to regain or maintain compliance with Nasdaq’s listing requirements. Such statements reflect current expectations and assumptions and are subject to risks and uncertainties. Actual outcomes could differ materially because of delays in completing corporate or market implementation requirements, changes in the number of outstanding shares, market conditions, trading volatility, the Company’s financial and operating performance, and the risks described in the Company’s most recent annual report on Form 20-F and other SEC filings. Forward-looking statements speak only as of the date made. The Company undertakes no obligation to update them, except as required by law.

Investor Relations Contact

iTonic Holdings Ltd

Investor Relations

Email: ir@ftzy.com.cn

LLYC

Jackson Lin

Phone: +1-646-717-4593

Email: jian.lin@llyc.global

New platform uses high-quality AI content as a user entry point and is designed to progressively integrate education products, research content, and global business services

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) — All In FutureTech Alliance Inc. (NASDAQ: AIFA) (“AIFA” or the “Company”) today announced the official launch of its new AIFA Digital Service Platform, designed for both consumer and business users.

The platform is an important component of AIFA’s broader digital business strategy. It is designed to build long-term user relationships through high-quality content focused on artificial intelligence, investing, and education, while progressively connecting users with the Company’s products and resources across education and workforce development, professional knowledge services, and global business services.

Unlike AIFA’s previously launched corporate website, which primarily serves corporate communications, company information, and investor relations functions, the new platform is intended to serve end users more directly, including individuals, families, professionals, entrepreneurs, and businesses interested in artificial intelligence, personal capability development, professional knowledge, and global business opportunities.

Through the new platform, AIFA aims to gradually establish an integrated user journey that moves from gaining insight through content, to building capabilities through education, and ultimately to addressing real-world needs through professional services.

High-Quality Content as a Long-Term User Entry Point

The AIFA Digital Service Platform adopts a content-first approach and provides bilingual Chinese and English content focused on artificial intelligence, investing, education, and global industry trends.

The planned content ecosystem includes daily in-depth articles, signed columns, global AI coverage, and thematic research, designed to help users develop a more systematic understanding of the technological, industrial, and social changes being driven by artificial intelligence.

The platform currently features a magazine-inspired editorial experience that emphasizes in-depth content, named authorship, and long-term reading value rather than traditional news-portal aggregation.

Connecting Content with Education and Workforce Development

Beyond content, AIFA plans to progressively integrate its education and workforce-development offerings into the platform, providing users at different stages with learning pathways ranging from basic AI literacy to professional capability development.

Planned education offerings include AI courses, professional training, bootcamps, Co-intelligence Academy programs, and other learning and membership products. Through these offerings, the Company seeks to help users move from understanding AI conceptually to developing practical and applicable skills.

Over the longer term, AIFA intends to apply artificial intelligence to areas including course development, knowledge organization, personalized learning, intelligent Q&A, and learning support, with the goal of improving both educational content production and service-delivery efficiency.

Supporting Global and Cross-Border Business Development

The AIFA Digital Service Platform is also expected to support the Company’s global business services.

For entrepreneurs, founders, and companies seeking to expand into international markets, the platform plans to provide overseas market information, case studies, policy and compliance content, international trade show and event information, and access to relevant global business-development resources.

AIFA is developing services around market entry, international trade shows, channel development, local partnerships, global brand expansion, and other cross-border business needs.

By connecting information with practical service access points, the Company aims to reduce the complexity of obtaining overseas market intelligence and professional resources, while progressively building cross-border service capabilities connecting Asia and North America.

Building a Digital User Ecosystem from Content to Services

AIFA intends to use the new platform to further develop long-term user relationships and digital service capabilities.

Through features including content subscriptions, personal Bookshelves, author following, research-report downloads, and product and service entry points, the platform is designed to progressively build a record of users’ interactions across reading, learning, and service needs. Current functionality already includes article saving, author following, and a personal Bookshelf.

Subject to applicable privacy, data-protection, and other legal requirements, the Company intends over time to use artificial intelligence to further improve user-needs identification, content recommendations, resource matching, and service delivery.

The Company believes that these long-term digital user relationships can provide an important foundation for the future development of AIFA’s AI-enabled service capabilities.

Management Commentary

Shanglong Li, Chairman of AIFA, commented:

“Artificial intelligence is rapidly changing how people acquire knowledge, develop skills, and make business decisions. We want AIFA to be more than a company that talks about AI. Our goal is to apply AI to real-world needs across users’ daily learning, work, and global business activities.”

“The launch of this new platform represents an important step in building long-term user relationships. A user may begin with a single article to better understand AI, and then continue into courses, research, and professional services. Our goal is to progressively connect content, education, and global business services through one unified platform, so users can move from information, to capability, to solving real-world problems within the AIFA ecosystem.”

AIFA Advances a Dual-Platform Digital Strategy

With the launch of the new consumer-facing digital service platform, AIFA is developing a complementary dual-platform digital architecture:

AIFA Corporate Website
Primarily serves shareholders, investors, media, business partners, and the capital markets, providing centralized access to the Company’s strategic direction, business portfolio, corporate governance, news, and investor relations information.

AIFA Digital Service Platform
Primarily serves consumers, professionals, creators, and business users, with the objective of building long-term user relationships and supporting business conversion through content, education, and professional services.

The Company believes the two platforms serve distinct but complementary functions—corporate and capital-markets communication on one side, and user services and business growth on the other—and together support AIFA’s long-term strategy of building an AI-enabled global service platform.

About All In FutureTech Alliance Inc.

All In FutureTech Alliance Inc. (NASDAQ: AIFA) is a publicly listed company focused on applying artificial intelligence to real-world business and service scenarios. The Company is developing businesses across education and workforce development, AI-enabled services, media and creator services, global commerce, and investment and research.

AIFA seeks to use artificial intelligence to improve knowledge creation, identify user needs, enhance resource matching and increase the efficiency and scalability of professional service delivery. The Company’s long-term objective is to build a scalable, AI-enabled global service platform serving individuals, organizations and businesses across multiple markets.

AIFA Corporate Website:
AIFA-Global.com

AIFA Digital Service Platform:
AIFA.one

Investor Relations:
ir@aifa-global.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable U.S. federal securities laws. These statements may include, without limitation, statements regarding the Company’s strategic direction, business development plans, use of artificial intelligence, anticipated expansion of its business platform, development of its education, media, global commerce, investment and research activities, and its long-term objective of building a scalable, AI-enabled global service platform.

Forward-looking statements are based on current expectations, estimates and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, among others, the Company’s ability to execute its business strategy, develop and commercialize its products and services, expand its customer and partner base, manage regulatory and compliance requirements, compete effectively, integrate new business initiatives, and obtain financing or other resources as needed.

Readers are cautioned not to place undue reliance on these forward-looking statements. Additional information regarding risks and uncertainties affecting the Company is contained in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law.

1. Acquiring 100% of East Coast Podiatry (five clinics) and Orchard Clinic (two clinics) for approximately S$4.0 million (approximately US$3.1 million)
2. Target Group generated FY2025 unaudited revenue of approximately S$9.1 million and unaudited normalized EBITDA of approximately S$1.2 million, based on unaudited management accounts
3. Sellers’ consideration shares subject to a lock-up
4. Adds an established clinical platform directly aligned with Cuprina’s wound-care and collagen technologies

SINGAPORE, Oct. 02, 2026 (GLOBE NEWSWIRE) — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or the “Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it has entered into Sale and Purchase Agreements (the “SPAs”) to acquire the entire issued and paid-up share capital of (i) East Coast Podiatry Centre Pte. Ltd. (“ECPC”), which operates East Coast Podiatry Clinic (“ECP”), the leading podiatry-focused chain in Singapore; and (ii) Orchard Clinic Management Pte. Ltd. (“OCM”), which operates Orchard Clinic (“ORC”), a Singapore women’s health and wellness clinic (ECPC and OCM together, the “Target Group”), through its direct wholly-owned subsidiary, Cuprina Holdings (BVI) Limited.

Under the SPAs, an aggregate purchase consideration of approximately S$4.0 million (approximately US$3.1 million) will be satisfied as follows (i) S$3.0 million (equivalent to approximately 75% of the consideration) in cash, comprising approximately S$0.5 million paid upon execution, S$1.35 million payable upon closing, and S$1.15 million in deferred cash consideration payable over a two-year period; and (ii) S$1.0 million¹ (equivalent to approximately 25% of the consideration) in Class A ordinary shares of the Company (the “Consideration Shares”). The consideration shares will be subject to lock-up as set forth in the SPAs and ancillary documents. Completion is subject to customary closing conditions and is expected to occur on or before November 1, 2026. Following completion, the Company expects to consolidate the financial results of the Target Group.

1. Consideration Shares is computed by diving the S1.0 million, by S$3.31², rounded down to the nearest whole share.
2. This being derived based on the average of Volume-Weighted Average Price (the “VWAP”) of each Class A ordinary share in Cuprina Holdings (Cayman) Limited on Nasdaq for the immediately preceding 30 consecutive trading days ending on the date of SPA of US$2.59 and at the exchange rate from SGD to USD of 0.7817.

For the year ended December 31, 2025, the Target Group generated combined unaudited revenue of S$9.1 million (approximately US$7.0 million) and combined unaudited normalized Earnings Before Interest, Tax, Depreciation and Amortization (“EBITDA”) of S$1.2 million (approximately US$0.9 million), based on the Target Group’s management accounts. These figures are derived from the Target Group’s unaudited management accounts, have not been reviewed or audited by the Company’s independent auditors, and may be subject to adjustment upon completion of the audit. 

ABOUT THE TARGET GROUP

The Target Group operates ECP and ORC, two established premium healthcare and wellness brands in Singapore. Founded and managed by an experienced leadership team, the Target Group is supported by mature, fully corporatized operating systems. Together, the Target Group represents a differentiated platform spanning conservative lower-limb care and specialized women’s wellness services, with a strong track record of operational execution and brand development.

ECP is widely recognized as a leading podiatry practice globally. It is a specialist outpatient clinic focused on the conservative management of the foot, ankle, and associated structures of the lower limb. Currently operating across five clinic locations in Singapore, ECP delivers comprehensive care through structured, multi-modal treatment strategies designed to support recovery, function, and long-term outcomes.

ECP specializes in biomechanical assessment, gait rehabilitation, orthotic therapy, diabetic wound care, and advanced podiatric treatment techniques, supported by modern clinical and diagnostic technologies. With over a decade of proven clinical and operational performance, ECP has built a globally recognized premium podiatry brand, attracting both local and international patients.

ORC is a premium women’s health, beauty and wellness center dedicated to prenatal body preparation and postnatal recovery, with a strong focus on abdominal and pelvic wellness. Currently operating across two clinic locations in Singapore, ORC delivers structured, program-based services in a refined and private environment designed specifically for women seeking personalized, high-quality wellness care.

ORC specializes in conservative treatment approaches for women before and after pregnancy, as well as through later life stages such as menopause. Its services support common conditions including pelvic floor concerns (vaginal laxity or dryness, pelvic organ prolapse), abdominal separation and bulge (diastasis recti), and post-pregnancy body changes.

Launched in 2020, ORC was a pioneer in this specialized segment and is recognized for its strong brand positioning, client experience, and differentiated service offering.

STRATEGIC RATIONALE

ECP is naturally complementary to Cuprina’s wound-healing focus, particularly in diabetic foot and lower-limb wound management, where podiatrists play a central role in conservative care. ECP’s established podiatry platform provides a practical clinical setting for the application and adoption of wound-care technologies, aligning with Cuprina’s ongoing work with podiatry and wound-care departments in Singapore.

In parallel, Cuprina’s collagen-based technologies for beauty complement ORC’s women’s post-partum recovery programs, particularly in relation to abdominal and tissue recovery such as diastasis recti. ORC’s structured, premium wellness environment provides a relevant platform for integrating collagen-supported recovery concepts within non-invasive women’s wellness services.

As wholly-owned subsidiaries, ECPC and OCM will be fully integrated into Cuprina’s operating structure, giving the Company complete control over clinical direction, branding, and expansion decisions, and entitling it to the full economic benefit of the Target Group’s earnings.

Together, Cuprina, ECP and ORC form a scalable, premium healthcare and wellness platform with a strong management foundation, loyal client base, and clear growth potential. The Target Group’s emphasis on conservative care, operational discipline, and brand-led service delivery positions it well for strategic partnerships and integration within a broader healthcare ecosystem.

“This acquisition marks a pivotal step in Cuprina’s evolution from a biomedical innovator into a fully integrated healthcare platform,” said Chief Executive Officer Mr. David Quek Yong Qi. “By taking full ownership of ECPC and OCM, we are acquiring high-quality clinical businesses with loyal patient bases, proven management teams, and direct synergies with our core wound-care and collagen technologies, and we retain the entirety of their earnings and the freedom to integrate them completely. We are building something differentiated: a company where biomedical innovation and frontline clinical delivery reinforce each other.”

MARKET TAILWINDS

Demand for podiatry services is supported by the rising prevalence of diabetes, aging populations, and a shift toward preventive foot care. These trends are pronounced in Singapore, where an aging population and a high burden of diabetes-related complications continue to drive demand for specialist lower-limb and diabetic foot care. According to a September 2026 report by Mordor Intelligence, the global podiatry services market is estimated at US$4.87 billion in 2026 and is projected to reach US$5.74 billion by 2031, with Asia Pacific the fastest-growing region at a compound annual growth rate of 4.65% over the period. For further information on this study, please see: https://www.mordorintelligence.com/industry-reports/podiatry-services-market

The women’s health and wellness segment presents an equally compelling opportunity. Rising awareness of pelvic health, postnatal recovery, and preventive women’s wellness is driving sustained demand across Southeast Asia for specialized, program-based care delivered in a premium, private clinical setting, which is the market position ORC has established, which Cuprina expects to build on.

About Cuprina Holdings (Cayman) Limited

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the infertility, medical waste recycling, and health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. For more information, please visit https://www.cuprina.com. 

FORWARD-LOOKING STATEMENTS

Certain statements contained in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the “Risk Factors” section of the Company’s filings with the U.S. Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Any forward-looking statements contained in this press release speak only as of the date hereof, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact
Investor Relations
c/o Blk 1090 Lower Delta Road #06-08
Singapore 169201
+65 8512 7275
Email: ir@cuprina.com.sg

Beijing, China, Oct. 02, 2026 (GLOBE NEWSWIRE) — ATA Creativity Global (“AACG” or the “Company”), (NASDAQ: AACG) announced today that on September 29, 2026, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”), notifying the Company that the minimum bid price per share for its American Depositary Shares (the “ADSs”), each representing two common shares, par value $0.01 per share, has been below $1.00 for a period of 31 consecutive business days and the Company therefore no longer meets the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2).

The notification received has no immediate effect on the listing of the Company’s ADSs on Nasdaq. Under the Nasdaq Listing Rules, the Company has until March 29, 2027 to regain compliance. If at any time during such 180-day period the closing bid price of the Company’s ADSs is at least $1 for a minimum of 10 consecutive business days, Nasdaq will provide the Company written confirmation of compliance.

If the Company does not regain compliance during such 180-day period, the Company may be eligible for an additional 180 calendar days, provided that the Company meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq except for Nasdaq Listing Rule 5550(a)(2), and provide a written notice of its intention to cure this deficiency during the second compliance period, by effecting a reverse stock split, if necessary. 

About ATA Creativity Global

ATA Creativity Global has been engaged in the business of providing international educational services company, with a focus on quality learning experiences that cultivate and enhance students’ creativity. As part of the Company’s ongoing business transformation, it completed the disposition of certain subsidiaries and variable interest entity on June 30, 2026, while continuing to operate its education business through its subsidiary in mainland China. For more information, please visit AACG’s website at https://aacg.online.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following:  the Company’s goals and strategies; the Company’s future business development; the Company’s future acquisition opportunities; the Company’s ability to identify any acquisition opportunities that fit with our business strategies; the Company’s ability to consummate an attractive acquisition and realize the benefits of such transaction; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission.  For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

At the Company
ATA Creativity Global
Ruobai Sima, CFO
+86 10 6518 1133 x 5518
simaruobai@acgedu.cn

NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) — Hall Chadwick Acquisition Corp. (NASDAQ: HCAC) (the “Company”) and REEcycle Holdings, Inc. (“REEcycle”) jointly announced the filing of the registration statement on Form S-4 with the U.S. Securities and Exchange Commission (the “SEC”) on October 1, 2026, in connection with the previously announced proposed business combination (the “Business Combination”). The registration statement includes a preliminary proxy statement/prospectus. It has not yet been declared effective by the SEC.

The Company and REEcycle have also released an updated investor presentation for use in connection with the Business Combination. The presentation has been furnished to the SEC as an exhibit to a Current Report on Form 8-K and is available on the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Additional Information and Where to Find It.

On October 1, 2026, the Company and REEcycle filed a registration statement on Form S-4 (the “Registration Statement”) with the SEC. The Registration Statement includes a proxy statement to be distributed to the Company’s shareholders in connection with the Company’s solicitation of proxies for the shareholder vote in connection with the Transactions (as defined in the Business Combination Agreement), the prospectus relating to the offer of securities to be issued in connection with the Merger, and other matters to be described in the registration statement. Following the effectiveness of the Registration Statement as declared by the SEC, the Company will mail a definitive proxy statement/prospectus and other relevant documents to its shareholders as of the record date established for voting on the Business Combination. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, HALL CHADWICK ACQUISITION CORP.’S SHAREHOLDERS AND OTHER INTERESTED PARTIES ARE URGED TO READ, WHEN AVAILABLE, THE JOINT PROSPECTUS/PROXY STATEMENT INCLUDED WITHIN THE REGISTRATION STATEMENT, AND ANY AMENDMENTS THERETO, AND THE DEFINITIVE PROXY STATEMENT/REGISTRATION STATEMENT AND ALL OTHER RELEVANT DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC IN CONNECTION WITH HALL CHADWICK ACQUISITION CORP.’S SOLICITATION OF PROXIES FOR THE EXTRAORDINARY GENERAL MEETING OF ITS SHAREHOLDERS TO BE HELD TO APPROVE THE BUSINESS COMBINATION AGREEMENT, MERGER AND OTHER MATTERS AS DESCRIBED IN THE PROXY STATEMENT/REGISTRATION STATEMENT BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT HALL CHADWICK ACQUISITION CORP., REECYCLE, AND THE PROPOSED TRANSACTIONS. Shareholders and other interested parties may obtain a copy of these documents, without charge, at the SEC’s website located at www.sec.gov or by directing a written request to the Company, Attn: Corporate Secretary, 1 North Bridge Road #18-06 High Street Centre Singapore, 179094.

NEITHER THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS, PASSED UPON THE MERITS OR FAIRNESS OF THE TRANSACTIONS OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS PRESS RELEASE. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.

Participants in the Solicitation.

REEcycle, the Company, and their respective directors, executive officers, management and employees, under SEC rules, may be deemed to be participants in a solicitation of proxies of the Company’s shareholders in connection with the Business Combination Agreement. Investors and shareholders may obtain more detailed information regarding the names, affiliations, and interests of the Company’s directors and executive officers in its filings with the SEC, including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on April 15, 2026, as amended on September 23, 2026, and as further amended on September 30, 2026. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies of the Company’s shareholders in connection with the Business Combination Agreement will be set forth in the proxy statement/registration statement, along with information concerning the interests of REEcycle’s and the Company’s participants in the solicitation. Such interests may in some cases be different from those of REEcycle’s or the Company’s equity holders generally. Investors and security holders may obtain free copies of these documents as described above.

Forward-Looking Statements

This press release includes “forward-looking statements” with respect to Hall Chadwick Acquisition Corp. (“HCAC”) and REEcycle Holdings, Inc. (“REEcycle”). Forward-looking statements generally relate to future events, including, without limitation, statements regarding the anticipated timing and benefits of the Transaction, and REEcycle’s future financial or operating performance. The expectations, estimates, and projections of the businesses of HCAC and REEcycle may differ from their actual results, and consequently, you should not rely on these forward-looking statements as predictions of future events. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expect,” “intend,” “will,” “estimate,” “project,” “budget,” “forecast,” “plan,” “anticipate,” “believe,” “predict,” “potential,” or “continue,” or the negatives of these terms or variations of them or similar terminology. In addition, these forward-looking statements include, without limitation, statements regarding REEcycle’s expectations with respect to future performance and anticipated financial impacts of the Transaction, the satisfaction of the conditions to, and the timing of the completion of the Transaction. Such forward-looking statements are subject to risks, uncertainties (some of which are beyond the control of REEcycle and/or HCAC), and other factors which could cause actual results to differ materially from those expressed or implied by such “forward-looking statements”, and consequently, you should not rely on these forward-looking statements with respect to HCAC and REEcycle. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by REEcycle and its management, as the case may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, without limitation: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of definitive agreements; (2) the outcome of any legal proceedings that may be instituted against REEcycle, HCAC or others following the announcement of the Transaction; (3) the inability to complete the Transaction due to the failure to obtain consents and approvals of shareholders or the SEC’s declaration of the effectiveness of the Registration Statement; (4) failure to obtain financing to complete the transactions or to satisfy other conditions to closing; delays or failures to obtain necessary regulatory approvals required to complete the transactions; (5) changes to the proposed structure of the Transaction as a result of applicable laws, regulations or conditions; (6) the risk that the Transaction disrupts current plans and operations of REEcycle; (7) projections, estimates and forecasts of revenue and other financial and performance metrics; (8) projections about industry trends and market opportunity; expectations relating to the demand for REEcycle’s services; (9) REEcycle’s ability to scale and grow its business; (10) the cash position of REEcycle following the closing; (11) the risk that the Transaction disrupts current plans and operations of REEcycle as a result of the announcement and consummation of the Transaction; (12) the ability to recognize the anticipated benefits of the Transaction, which may be affected by, among other things, competition, the ability of REEcycle to successfully commercialize its business, and REEcycle’s ability to source and maintain key relationships with management and key employees; (13) the ability of the combined company to grow and manage growth profitably, continue developing its properties, maintain relationships with customers and suppliers, and retain its management and key employees; (14) costs related to the Transaction; (15) the possibility that REEcycle and/or its related entities may be adversely affected by other economic, business, and/or competitive factors; (16) risks relating to REEcycle’s anticipated operations and business; (17) the risk that REEcycle does not ever enter into any definitive agreements in connection with commercialization of its technology; (18) the risk that REEcycle is pursuing an emerging market; (19) the amount of redemption requests made by the HCAC public shareholders; and (20) other risks and uncertainties set forth under “Risk Factors” and other documents filed, or to be filed, with the SEC by HCAC and/or REEcycle, including the Registration Statement, and HCAC’s other filings with the SEC, as well as any further risks and uncertainties to be contained in the Proxy Statement/Prospectus filed after the date of this press release. In addition, there may be additional risks that neither HCAC nor REEcycle presently know, or that REEcycle currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as may be required by law, REEcycle and HCAC do not undertake any duty to update these forward-looking statements. The inclusion of any statement in this communication does not constitute an admission by REEcycle and HCAC, or any other person, that the events or circumstances described in such statement are material.

No Offer or Solicitation.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of any such jurisdiction. This communication is not, and under no circumstances is to be construed as, a prospectus, an advertisement or a public offering of the securities in the United States or any other jurisdiction. No offer of securities shall be made except by means of a prospectus filed with the SEC meeting the requirements of Section 10 of the Securities Act, or exemptions therefrom. Investors should consult with their counsel as to the applicable requirements for the Company to avail itself of any exemption under the Securities Act.

Investor Relations Contact:

REEcycle

Sandy Noyes
sandy@reecycleinc.com

HCAC

Alex Bono
abono@hallchadwick.com

Media Contact:

REEcycle

Sandy Noyes
sandy@reecycleinc.com

HCAC

Mike Willesee
mwillesee@hallchadwick.com.au

Press Release

Information on the total number of voting rights and shares of 74Software share capital as of September 30, 2026

Paris, October 2, 2026 – In accordance with Articles L.233-8 II and R.225-73 I of the French Commercial Code (Code de Commerce) and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers (RGAMF), 74Software hereby informs its shareholders that, as of September 30, 2026:

• Total number of shares is 29,746,194.
• Total number of theoretical voting rights is 42,055,360.

It is calculated according to the total number of shares with voting rights, including those whose voting rights have been suspended, and is used to declare threshold crossing by shareholders in accordance with Article 223-11 of the RGAMF.

• Number of exercisable voting rights is 41,172,577.

Disclaimer

This document is a translation into English of an original French press release. It is not a binding document. In the event of a conflict in interpretation, reference should be made to the French version, which is the authentic text.

About 74Software

74Software is an enterprise software group founded through the combination of Axway and SBS – independently operated leaders with unique experience and capabilities to deliver mission-critical software for a data driven world. A pioneer in enterprise integration solutions for 25 years, Axway supports major brands and government agencies around the globe with its core line of MFT, B2B, API, and Financial Accounting Hub products. SBS empowers banks and financial institutions to reimagine tomorrow’s digital experiences with a composable cloud-based architecture that enables deposits, lending, compliance, payments, consumer, and asset finance services and operations to be deployed worldwide. 74Software serves more than 12,000 companies, including over 1,500 financial service customers. To learn more, visit 74Software.com

Contacts – Investor Relations:

Arthur Carli – +33 (0)1 47 17 24 65 – acarli@74software.com

Chloé Chouard – +33 (0)1 47 17 21 78 – cchouard@74software.com

Get the latest 74Software IR updates in your inbox by subscribing to our mailing list here.

Attachment

• 02102026_74Software_PR_voting_rights_September2026_VE

THIS ANNOUNCEMENT RELATES TO THE PUBLIC DISCLOSURE OF INSIDE INFORMATION UNDER ARTICLE 17 OF REGULATION (EU) NO 596/2014 AND CONTAINS INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THAT REGULATION.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.

ART SHARE 002 S.A.

16, rue E. Ruppert, L-2453 Luxembourg, Grand Duchy of Luxembourg
R.C.S. Luxembourg B273672 | LEI 254900OEKYEX6EFPVO79
ARTEX Global Markets ticker BAC1EU | Class B shares ISIN LU2583605592

For immediate release

Art Share 002 announces third party tender offer by NORVAULT AG for Class B shares

Luxembourg, 2 October 2026, Time 1500CET

Art Share 002 S.A. (the Company), the sole holder of Three Studies for Portrait of George Dyer, 1963 by Francis Bacon and the issuer of the Class B shares admitted to trading on the Multilateral Trading Facility (MTF) operated by ARTEX Global Markets, announces that it has been informed by NORVAULT AG (NORVAULT), a Liechtenstein company, that NORVAULT is undertaking a voluntary off-market cash and exchange tender offer for up to 54,999 Class B shares in the Company.

The Company considers this information relevant to investors because completion of the tender at or near its maximum size may affect ownership concentration, the number of Class B shares available for trading, liquidity and the market price of the Class B shares. The Company cannot predict whether, or to what extent, any such effects will occur.

Principal terms communicated by NORVAULT

• Cash tender. EUR 70.00 for each share accepted by NORVAULT.
• Exchange tender. Eligible holders may elect to receive NORVAULT Bacon Series 001 Notes. The number of Notes is calculated at 97.5% of the accepted exchange shares and rounded up to the next whole Note; exchange elections must be made in whole multiples of 100 shares. The Notes are obligations of NORVAULT and do not confer shareholder rights in the Company.
• Notes. The Notes are euro-denominated, tokenised, secured, unsubordinated, limited-recourse debt obligations of NORVAULT. They carry no interest and have no fixed maturity. They do not confer ownership of the Company, the tendered shares or the Artwork, or any voting, dividend or other shareholder rights in the Company. Each Note is intended to be represented by one Canton Token, subject to the final register and wallet arrangements.

The Offer is expected to open on 05 October 2026, expire on 21 October 2026 and settle on 30 October 2026. These dates may change, and intermediaries may apply earlier deadlines. The complete terms, conditions, eligibility requirements and procedures are contained in NORVAULT’s Tender Offer Memorandum and related documents available at www.cantra.io.

Effect on Art Share 002 and Company position

The Offer is not made by the Company and is not a repurchase, issue or cancellation of its shares. The Company will not receive any proceeds and is not the issuer, guarantor or obligor of the Notes. The Offer does not change the Company’s share capital or the rights attaching to the Class B shares.
The Board does not recommend that shareholders tender or refrain from tendering. Each holder should make its own decision by reference to NORVAULT’s final documents and its own circumstances. If the Offer completes, the transfer of existing shares to NORVAULT may increase ownership concentration and reduce the number of Class B shares available for trading, which may affect liquidity and the market price.

Contacts and person responsible

Investor relations: Investor-relations@artshare002.com

Press contact: Amit Sharma – Amit.sharma@artexgm.com

About Art Share 002

Art Share 002 S.A. is a public limited liability company (société anonyme) incorporated under the laws of the Grand Duchy of Luxembourg and existing as a securitisation undertaking (organisme de titrisation) within the meaning of the Luxembourg law of 22 March 2004 on securitisation, as amended. Its principal activity is to hold and securitise Three Studies for Portrait of George Dyer, 1963 by Francis Bacon and the risks associated with the Artwork. The Class B shares are admitted to trading on ARTEX Global Markets.

The Company is managed by its board of directors: Ursula Schmidt, Edouard de Burlet and Ronan Le Bouc.

Regulatory information
The person responsible for arranging the release of this announcement on behalf of the Company is Edouard de Burlet, Director. The date and time of communication to the media is 02 October 2026 at 1500 CET.

Information in this announcement concerning NORVAULT, the Offer and the Notes has been provided by NORVAULT and is included solely to explain the transaction affecting the Class B Shares. Art Share 002 is not responsible for the conduct, funding, acceptance, allocation, settlement or completion of the Offer, or for the issue, custody, security, performance or payment of the Notes, each of which is a matter for NORVAULT and the relevant intermediaries. Nothing in this announcement excludes or limits any responsibility or liability of Art Share 002 that cannot lawfully be excluded or limited, including its responsibility for the accuracy and non-misleading nature of this announcement. The Offer and the Notes are not being made or offered in the United States or to, or for the account or benefit of, U.S. persons, or in Australia, Canada, Japan, New Zealand, South Africa or any other jurisdiction where doing so would be unlawful. The restrictions and definitions in NORVAULT’s final documents apply.

This is an issuer disclosure by Art Share 002 and does not constitute an offer, invitation, solicitation, investment advice or recommendation. The Offer and any offer of Notes are made solely by NORVAULT under its final documents. No prospectus for the Notes has been approved by any competent authority.